GO:2000494 positive regulation of interleukin-18-mediated signaling pathway

The Gene Ontology (GO) term GO:2000494, positive regulation of interleukin-18-mediated signaling pathway, is a biological process that encompasses any molecular event that enhances the initiation, intensity, or duration of signaling downstream of the cytokine interleukin-18 (IL-18). IL-18 is a member of the IL-1 cytokine family and is best known for its ability to induce interferon gamma (IFN-gamma) production in T cells and natural killer (NK) cells, thereby bridging innate and adaptive immunity. The pathway begins when IL-18 binds its receptor complex, leading to recruitment of adaptor proteins and activation of NF-kB and other transcription factors that drive IFN-gamma expression. Positive regulation of this pathway is therefore central to immune amplification and host defense. Researchers study GO:2000494 to understand how inflammatory responses are tuned, how pathogens evade immunity, and how chronic inflammation arises when this regulation goes awry. For example, the hepatitis B virus e antigen (HBeAg) has been shown to downregulate IL-18-mediated signaling and IFN-gamma expression, illustrating that viruses can directly antagonize positive regulators of this pathway. Such findings highlight the importance of identifying the host factors that positively regulate IL-18 signaling and of developing experimental models to test their function. This article provides a research-grade overview of GO:2000494, covering its definition, mechanistic stages, key genes, disease relevance, and state-of-the-art methods including CRISPR-based models. All statements are grounded in the verified literature.

GO:2000494 is defined as any process that activates or increases the frequency, rate or extent of the interleukin-18-mediated signaling pathway. In other words, it includes molecular events that amplify or sustain the cellular response to IL-18, from receptor engagement to downstream gene expression such as IFN-gamma. This term is a child of positive regulation of signal transduction and is specific to the IL-18 signaling cascade.

Understanding positive regulation of IL-18-mediated signaling is essential because this pathway is a central amplifier of inflammatory and immune responses. It controls IFN-gamma production, which is critical for activating macrophages and cytotoxic lymphocytes to eliminate infected or malignant cells. Conversely, excessive or prolonged positive regulation can drive tissue damage and autoimmune pathology. Moreover, pathogens such as hepatitis B virus can interfere with this regulation to establish chronic infection. Thus, dissecting the molecular players that positively regulate IL-18 signaling offers therapeutic opportunities for infectious diseases, cancer, and inflammatory disorders.

The following genes and proteins are central to the positive regulation of IL-18-mediated signaling, based on published literature.

Positive regulation of IL-18-mediated signaling is itself controlled at multiple levels. Upstream, inflammasome activation and caspase-1 activity determine the availability of mature IL-18. Receptor expression levels and post-translational modifications can modulate sensitivity to IL-18. Intracellularly, the balance between activating kinases (IRAK1/4, TBK1, IKK-beta) and inhibitory phosphatases or ubiquitin ligases tunes signal strength. Viral proteins such as HBeAg can directly antagonize positive regulators, shifting the balance toward immune evasion. Additionally, cytokines like IL-12 can synergize with IL-18 to enhance IFN-gamma production, effectively acting as positive regulators of the pathway.

IL-18-mediated signaling is crucial for controlling intracellular pathogens, and positive regulation of this pathway enhances IFN-gamma-dependent immunity. However, pathogens can counteract these positive regulators. For example, hepatitis B virus e antigen (HBeAg) downregulates IL-18-mediated signaling and IFN-gamma expression, contributing to viral persistence and chronic hepatitis B. Understanding how positive regulation is subverted may inform immunotherapeutic strategies.

Excessive positive regulation of IL-18 signaling can lead to uncontrolled inflammation and tissue damage. Elevated IL-18 activity has been associated with autoinflammatory conditions such as macrophage activation syndrome and autoimmune diseases including rheumatoid arthritis and inflammatory bowel disease. Targeting positive regulators could provide therapeutic benefit.

IL-18 signaling promotes antitumor immunity by inducing IFN-gamma and activating NK and T cells. Positive regulators of this pathway are therefore potential targets for cancer immunotherapy. Conversely, chronic inflammation driven by IL-18 may promote tumorigenesis in some contexts, highlighting the need for context-dependent modulation.

Measuring IFN-gamma and other downstream target genes by RNA-seq or qPCR provides a quantitative readout of positive regulation of IL-18 signaling. Comparing wild-type and knockout cells after IL-18 stimulation reveals the contribution of specific genes.

Western blotting for phosphorylated IRAK1, NF-kB, and STAT4 can assess pathway activation. Mass spectrometry-based proteomics can identify novel interaction partners and post-translational modifications that positively regulate signaling.

Flow cytometry for intracellular IFN-gamma is a standard method to quantify IL-18 responses in T and NK cells. Luciferase reporter assays driven by IFN-gamma promoter elements enable high-throughput screening of positive regulators.

Genome-wide CRISPR knockout or activation screens can identify genes whose loss or gain alters IL-18-induced IFN-gamma production. These unbiased approaches are powerful for discovering novel positive regulators.

Researchers studying positive regulation of interleukin-18-mediated signaling pathway-related genes often need to determine whether a candidate gene is causally involved in enhancing IL-18 responses or is merely correlated. EDITGENE provides end-to-end CRISPR services to generate precisely engineered cell models that answer these questions with rigor and reproducibility.

GO:2000494, positive regulation of interleukin-18-mediated signaling pathway, is a critical biological process that amplifies immune responses through enhanced IL-18 signaling and IFN-gamma production. Its precise regulation is essential for host defense, but its dysregulation contributes to inflammatory diseases and viral immune evasion. By leveraging CRISPR-based models and multi-omics methods, researchers can dissect the molecular players and translate these insights into novel therapeutics.